Skip to main content
Study of 364 Japanese myositis (IIM) pts - 42 (11.4%) had cancer-assoc myositis (CAM); 30/42 Dx w/in ±1 yr of IIM. CA r

Dr. John Cush RheumNow

1 month 2 weeks ago
Study of 364 Japanese myositis (IIM) pts - 42 (11.4%) had cancer-assoc myositis (CAM); 30/42 Dx w/in ±1 yr of IIM. CA risk incr ±3 yrs of IIM (SIR 2.54), highest 1st yr (SIR 8.66). 5 factors predicted CAM: TIF1γ +, ^CRP, dermatomyositis, older age, +FHx CA (AUC 0.86; sensitivity https://t.co/9ojTWTK5kO
The British Society for Rheumatology has issued its first guideline dedicated solely to pain in inflammatory arthritis (IA)—covering RA, PsA, axial SpA and JIA.
Congratulations to Dr. Edoardo Cipolletta (U Nottingham) - winner of Gout, Urate, and Crystal Deposition Disease Best Ph

Dr. John Cush RheumNow

1 month 2 weeks ago
Congratulations to Dr. Edoardo Cipolletta (U Nottingham) - winner of Gout, Urate, and Crystal Deposition Disease Best PhD Thesis Award. Read his insightful interview on his reasearch on #gout. https://t.co/5i3hEV6PJX https://t.co/XV5trvEonW
Substudy of 131 Still’s dz pts from the Autoinflammatory Dz (AIDA) registry. 38% underdosed w/ canakinumab (CAN) vs 62

Dr. John Cush RheumNow

1 month 2 weeks ago
Substudy of 131 Still’s dz pts from the Autoinflammatory Dz (AIDA) registry. 38% underdosed w/ canakinumab (CAN) vs 62% appropriately dosed (300 mg q4wks or 4 mg/kg). Underdosed CAN had lower odds of long-term remission & D/C CAN (3.9% vs 19%) https://t.co/l94zB9NkKv https://t.co/D8FNUXS0nv
CDC warns of an association betw severe CNS arboviral disease, w/ neurologic sequelae in pts receiving anti-CD20 mAbs (r

Dr. John Cush RheumNow

1 month 2 weeks ago
CDC warns of an association betw severe CNS arboviral disease, w/ neurologic sequelae in pts receiving anti-CD20 mAbs (rituximab, ocrelizumab, ofatumumab, obinutuzumab, etc). West Nile virus was the most common arbovirus, but there are others; mortality up to 40%. Most arbovirus https://t.co/WWg41fsRgr
JAMA has updated its guidance for the acceptable use of artificial intelligence (AI) in authoring a medical publication. Despite growing AI use, very low rates of disclosure of AI use have been reported. This update provides specific information about what is permitted and not permitted, and what needs to be disclosed.
From 1975 -2025, incidence of Kawasaki dz (KD) increased 16.1-fold in Japan, KD cases 15 032 and& 14 809 in 202

Dr. John Cush RheumNow

1 month 2 weeks ago
From 1975 -2025, incidence of Kawasaki dz (KD) increased 16.1-fold in Japan, KD cases 15 032 and& 14 809 in 2023 & 2024, but during COVID #s dropped to 10 333 in 2022. KD #s rebounded after the COVID-19: Infants showed minimal changes, but kids 5-9 had the greatest increase https://t.co/j0BL2ZELXn
Lee, Levinson, and Makris have published an approach to evaluating inflammatory joint pain in older adults in JAMA Internal Medicine. While intended to be a practical guide for primary care clinicians, the tenets and clues ring true for all.
MoonLake announced positive phase 3 data from its IZAR-1 RCT using its dual A/F IL-17 inhibitor sonelokimab, showing sig

Dr. John Cush RheumNow

1 month 2 weeks ago
MoonLake announced positive phase 3 data from its IZAR-1 RCT using its dual A/F IL-17 inhibitor sonelokimab, showing significant responses at week 16: 66% ACR20, 42% ACR50, 41% minimal disease activity (MDA), & 61% PASI90 at week 16. a 2nd IZAR-2 PsA RCT is in progress https://t.co/eX0cxekRKG
NP Salaries: in 7 specialties, NPs now avg >$150,000/yr, with the avg annual salary surpassing $137,000 in 2026 accor

Dr. John Cush RheumNow

1 month 2 weeks ago
NP Salaries: in 7 specialties, NPs now avg >$150,000/yr, with the avg annual salary surpassing $137,000 in 2026 according toBureau of Labor Statistics. https://t.co/LlGFxkvEj5 https://t.co/h5bKsrnm4k
Wealth and Where you Live Influences Outcomes
  • EurekAlert!
Patients from wealthier European countries tend to start treatment with biologics earlier but also stop or switch treatment earlier. They also experience lower disease activity at treatment start than patients in middle- and low-income countries.
Multimodal & multidisciplinary Tx (MMT) are underutilized in adults w/ chronic pain. Study of 347 Chr pain pts - 60%

Dr. John Cush RheumNow

1 month 2 weeks ago
Multimodal & multidisciplinary Tx (MMT) are underutilized in adults w/ chronic pain. Study of 347 Chr pain pts - 60% used non-opioid meds; 29% used opioids & only 11% MMT. Older age & high intensity pain assoc w/ Opioids. MMT had more complex pain w/ greater pain interference, https://t.co/iF0UQeut9b
JAMA has updated its guidance for the acceptable use of AI in authoring a Medical Publication. Despite growing AI use, v

Dr. John Cush RheumNow

1 month 2 weeks ago
JAMA has updated its guidance for the acceptable use of AI in authoring a Medical Publication. Despite growing AI use, very low rates of disclosure of AI use have been reported. This is about what is permitted & not permitted & what needs to be disclosed. https://t.co/zti0OnvBV0 https://t.co/Y1C3MfJ27c
×